@article{oberkirchner_linder_dunston_bizikova_olivry_2011, title={Metaflumizone–amitraz (Promeris)‐associated pustular acantholytic dermatitis in 22 dogs: evidence suggests contact drug‐triggered pemphigus foliaceus}, volume={22}, url={http://www.scopus.com/inward/record.url?eid=2-s2.0-80052525616&partnerID=MN8TOARS}, DOI={10.1111/j.1365-3164.2011.00974.x}, abstractNote={Abstract Promeris Duo (PD) is a novel topical flea and tick preventative for dogs, which is also licensed for treatment of canine demodicosis. In this article, we present 22 dogs that all developed pemphigus foliaceus (PF)‐like cutaneous drug reactions at the site of PD application. In eight dogs, the lesions were restricted to the application site (localized group). Signs of systemic illness were reported in three dogs, and four required immunosuppressive treatment. Direct immunofluorescence for IgG was positive in four dogs, although circulating antikeratinocyte IgG could not be detected in any tested sera. Complete remission was achieved in all dogs, with one patient still remaining on treatment. Fourteen dogs developed skin lesions at the application site as well as other noncontiguous areas (distant group). Systemic signs were reported in 11 dogs, and immunosuppression was required in 10 cases. Direct and indirect immunofluorescence tests were positive for antikeratinocyte autoantibodies in 10 of 13 and six of 10 patients with distant disease, respectively. Complete remission was achieved in 10 of 13 dogs with distant disease; one‐third are still on treatment. Histological changes were similar to canine PF. Desmosomal architectural changes, assessed by desmoglein‐1 immunostaining, were also similar to those of dogs with spontaneous autoimmune PF. Apoptosis did not appear to contribute to lesion formation, in either autoimmune or PD‐associated PF. In conclusion, PD has the potential of triggering a variant of PF that resembles spontaneously occurring autoimmune PF at clinical, morphological, immunological and treatment outcome levels.}, number={5}, journal={Veterinary Dermatology}, author={Oberkirchner, Ursula and Linder, Keith E. and Dunston, Stan and Bizikova, Petra and Olivry, Thierry}, year={2011}, month={Mar}, pages={436–448} }
 @article{oberkirchner_linder_olivry_2011, title={Successful treatment of a novel generalized variant of canine discoid lupus erythematosus with oral hydroxychloroquine}, volume={23}, url={http://www.scopus.com/inward/record.url?eid=2-s2.0-84855339558&partnerID=MN8TOARS}, DOI={10.1111/j.1365-3164.2011.00994.x}, abstractNote={Abstract Discoid lupus erythematosus (DLE) is a common canine autoimmune disease that usually manifests as a localized ulcerative and scarring nasal dermatitis. We report herein a generalized variant of canine DLE successfully treated with the antimalarial immunomodulator hydroxychloroquine (HCQ). A 9‐year‐old hairless Chinese crested dog was presented with annular and polycyclic hyperpigmented and scaly skin lesions with central erosions, hypopigmentation and/or scarring on the trunk, neck and lateral extremities. Associated systemic signs were not seen. The clinical diagnosis of generalized DLE was supported by the demonstration of lymphocyte‐rich interface dermatitis with epidermal atrophy and dermo‐epidermal deposition of immunoglobulins and activated complement. As for human DLE, treatment was initiated with HCQ at 5 mg/kg once daily along with 2 weeks of 0.1% tacrolimus ointment and restriction of sun exposure. Over the following year, complete remission was maintained with HCQ at 5 mg/kg orally once daily with the exception of three relapses; two occurred during treatment induction and the third arose when the frequency of HCQ administration was reduced to every other day. Disease flares were controlled with 0.1% tacrolimus ointment alternating with 0.1% prednicarbate cream once daily for 5–10 days. Altogether, adverse drug events were not seen with this regimen. In summary, clinically, histologically and immunologically, this dog’s disease mirrored the generalized discoid variant of chronic cutaneous lupus erythematosus of humans. The apparent benefit of HCQ, its safety and low cost warrant future investigations of its use for treatment of canine cutaneous lupus variants.}, number={1}, journal={Veterinary Dermatology}, author={Oberkirchner, Ursula and Linder, Keith E. and Olivry, Thierry}, year={2011}, month={Jul}, pages={65–16} }
 @article{oberkirchner_linder_zadrozny_olivry_2010, title={Successful treatment of canine necrolytic migratory erythema (superficial necrolytic dermatitis) due to metastatic glucagonoma with octreotide}, volume={21}, url={http://www.scopus.com/inward/record.url?eid=2-s2.0-77956458558&partnerID=MN8TOARS}, DOI={10.1111/j.1365-3164.2009.00876.x}, abstractNote={Abstract Necrolytic migratory erythema (NME; also known as superficial necrolytic dermatitis) is a syndrome most often associated with certain chronic liver diseases or pancreatic glucagonomas. In humans with glucaconoma‐associated NME, skin lesions usually respond to octreotide, a somatostatin analogue that inhibits glucagon release. In this report an 11‐year‐old golden retriever dog with pancreatic glucononoma and metastasis to the regional lymph nodes, spleen and liver was diagnosed with NME. The dog exhibited erosions, ulcers and crusts on the paws, pressure points, muzzle, periocular area and prepuce. The dog was also anorexic and had difficulty walking. Because metastasis precluded surgery, treatment was initiated with subcutaneous octreotide (2 μg/kg twice daily). Skin lesions and systemic clinical signs improved markedly within 5 days. The dosage was increased to nearly 3 μg/kg twice daily and signs almost completely resolved within 10 days. Anorexia was the major adverse effect observed. During the following month, both dosage (1–3.7 μg/kg) and frequency (two to four times daily) of the octreotide injections were adjusted to permit control of clinical signs while maintaining adequate appetite. Temporary cessation of octreotide administration resulted in the rapid recurrence of skin lesions. Resuming injections led to improvement of clinical signs within 48 h. The dog was later euthanized because of progressive metastatic disease. In conclusion, subcutaneous octreotide injections were beneficial in this dog with glucagonoma‐associated NME. This somatostatin analogue could be a valuable option to treat canine patients with non‐resectable or relapsing pancreatic glucagonoma‐associated NME.}, number={5}, journal={Veterinary Dermatology}, author={Oberkirchner, Ursula and Linder, Keith E. and Zadrozny, Leah and Olivry, Thierry}, year={2010}, month={May}, pages={510–516} }